celecoxib has been researched along with Cervix Dysplasia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grabosch, SM | 2 |
| Shariff, OM | 2 |
| Helm, CW | 2 |
| Wulff, JL | 1 |
| Rader, JS | 1 |
| Sill, MW | 1 |
| Beumer, JH | 1 |
| Lankes, HA | 1 |
| Benbrook, DM | 1 |
| Garcia, F | 1 |
| Trimble, C | 1 |
| Tate Thigpen, J | 1 |
| Lieberman, R | 1 |
| Zuna, RE | 1 |
| Leath, CA | 1 |
| Spirtos, NM | 1 |
| Byron, J | 1 |
| Thaker, PH | 1 |
| Lele, S | 1 |
| Alberts, D | 1 |
| Farley, JH | 1 |
| Truong, V | 1 |
| Goo, E | 1 |
| Uyehara, C | 1 |
| Belnap, C | 1 |
| Larsen, WI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)[NCT00081263] | Phase 2 | 130 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Whether or not patients with CIN 2/3 or CIN 3 upon entry experience a complete remission (or partial regression to CIN 1) in the post-treatment excisional biopsy. (NCT00081263)
Timeframe: Post treatment evaluation was done 14 to 18 weeks after treatment randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Celecoxib) | 40 |
| Arm II (Placebo) | 34.1 |
Number of participants with a grade of 3 or higher during the treatment period. (NCT00081263)
Timeframe: Assessed every cycle while on treatment, 30 days after the last cycle of treatment
| Intervention | participants (Number) | |
|---|---|---|
| Gastrointestinal | Pain | |
| Arm I (Celecoxib) | 1 | 0 |
| Arm II (Placebo) | 0 | 1 |
2 reviews available for celecoxib and Cervix Dysplasia
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 In | 2018 |
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitor | 2014 |
2 trials available for celecoxib and Cervix Dysplasia
| Article | Year |
|---|---|
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adolescent; Adult; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Doub | 2017 |
A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Fe | 2006 |